GlassScriptPhysician profile
Jonathan P Perlman
NPI 1972510477
$2,645.74
in general payments reported to CMS, 2019-2025
15 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $159 · 2021: $252 · 2022: $150 · 2023: $341 · 2024: $708 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $734.93 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rhopressa |
| Genentech USA, INC. | $395.13 | 2022-2024 | Vabysmo |
| Biotissue Holdings INC. | $381.44 | 2024 | |
| Aerie Pharmaceuticals, INC. | $220.85 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $143.92 | 2023 | Acthar |
| Genentech, INC. | $121.74 | 2025 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $109.79 | 2020 | |
| Apellis Pharmaceuticals, INC. | $104.75 | 2024 | Syfovre |
| Ellexiscience | $104.50 | 2019 | |
| Abbvie INC. | $87.29 | 2019 | |
| Thea Pharma INC. | $47.17 | 2023 | Iyuzeh |
| Allergan, INC. | $29.88 | 2020 | |
| Horizon Therapeutics Plc | $24.26 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Perlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.